LINEAGE CELL THERAPEUTICS INC LCTX 深 滬
等待開盤 10-03 09:30:00 美东时间
1.72
+0.030
+1.78%
華盛通- 最 高1.744
- 今 開1.73
- 成交量 94.25万股
- 最 低 1.69
- 昨 收 1.69
- 總市值 3.92亿
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.3651
- 委 比 0.00%
- 總股本 2.28亿
- 歷史最高 3.132
- 量 比 0.49
- 振 幅 3.20%
- 歷史最低 0.3651
- 每 手 1
- 風險率 0.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lineage Therap (LCTX) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lineage The...
09-08 20:56
Lineage Cell Therapeutics Announces Launch Of A New Islet Cell Transplant Program Targeting Type 1 Diabetes
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the
09-08 20:01
Lineage And William Demant Collaborate Through Investment To Develop ReSonance For Hearing Loss
Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of development costs to be contributed by William Demant Invest
08-26 20:05
Update: Lineage Cell Therapeutics Q2 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 159.26 percent. This is a 133.33 percent decrease over losses of $(0.03) per
08-13 04:04
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
A Peek at Lineage Cell Therapeutics's Future Earnings
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earni...
08-12 04:02
Lineage Cell Therapeutics Announced The First Chronic Spinal Cord Injury Patient Has Been Treated In The Company's DOSED Clinical Study, Evaluating A New Parenchymal Spinal Delivery System
The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery system, a novel delivery device developed to deliver OPC1 directly to the site of injury in patients with spinal cord
08-04 20:10
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
Lineage Therap Reports Promising OpRegen Study Results
An announcement from Lineage Therap ( ($LCTX) ) is now available. Lineage Cell ...
06-24 02:55
